8-K: PAVmed 1-for-30 Reverse Split to Meet Nasdaq Minimum Bid

PAVmed Inc. will implement a 1-for-30 reverse stock split and reduce authorized shares to regain compliance with Nasdaq's minimum bid price requirement, effective January 2, 2026.

Summary

• PAVmed Inc. will execute a 1-for-30 reverse stock split of its common stock.
• The reverse stock split will become effective on January 2, 2026, at 12:01 a.m. Eastern Time, with trading on a split-adjusted basis commencing at market open on the same day.
• The primary purpose of the reverse split is to regain compliance with the Nasdaq Capital Market's $1.00 minimum bid price requirement (Nasdaq Listing Rule 5550(a)(2)).
• The company's authorized shares of common stock will be reduced from 250,000,000 to 25,000,000.
• Fractional shares resulting from the split will be rounded up to the nearest whole share, with no cash or other consideration paid.
• Outstanding stock options, convertible securities (including Series B and C preferred stock, and a convertible note), and shares reserved under equity incentive plans will be proportionately adjusted.
• The trading symbol (PAVM) will remain unchanged, but the CUSIP number for the common stock will change to 70387R 502.

Sentiment

Score: 4

Explanation: The filing addresses a critical compliance issue (Nasdaq listing) which is a positive, as it aims to prevent delisting. However, the underlying need for a reverse split due to a low stock price is inherently a negative signal about past performance and market perception. The action itself is a necessary corrective step rather than a growth-oriented development.

Positives

• The reverse stock split is intended to bring the company into compliance with Nasdaq's minimum bid price requirement, potentially preventing delisting and preserving market liquidity.
• The company expects the closing bid price of its common stock to increase above the $1.00 per share requirement.
• The board believes the relative increase in the number of shares of common stock authorized for issuance (post-split) is in the best interests of the company and its stockholders, providing future corporate flexibility.

Negatives

• The necessity of a reverse stock split indicates that the company's common stock price has fallen below Nasdaq's minimum bid requirement for an extended period, signaling past underperformance or market challenges.
• Reverse stock splits can sometimes be perceived negatively by investors and may not always lead to a sustained increase in stock price or improved market sentiment.
• No assurances are provided that the reverse split will definitively enable the company to maintain its Nasdaq listing.

Risks

• There is no assurance that the reverse stock split will enable the company to maintain its Nasdaq listing.
• Forward-looking statements involve substantial risks and uncertainties, which could cause actual results, performance, or achievements to differ materially from those expressed or implied.
• Risks include volatility in the price of PAVmed's and Lucid Diagnostics' common stock, as well as general economic and market conditions.
• Uncertainties inherent in research and development, including the cost and time required to advance products to regulatory submission.
• Uncertainty regarding whether regulatory authorities will be satisfied with the design and results from clinical and preclinical studies.
• Uncertainty regarding whether and when PAVmed's and Lucid Diagnostics' products are cleared by regulatory authorities.
• Market acceptance of PAVmed's and Lucid Diagnostics' products once cleared and commercialized.
• PAVmed's and Lucid Diagnostics' ability to raise additional funding as needed.
• Other competitive developments.
• Further risks and uncertainties are detailed in the company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

Future Outlook

The company expects the reverse stock split to increase its common stock's closing bid price above the $1.00 per share requirement, thereby regaining compliance with Nasdaq's listing rules. It believes this action will enable it to maintain its Nasdaq listing, though no assurances are provided.

Management Comments

• "The Company expects that the closing bid price of the Common Stock will increase above the $1.00 per share requirement to regain compliance with the minimum bid price requirement."
• "Although no assurances can be provided, the Company further believes that Reverse Split will enable the Company to maintain its Nasdaq listing."
• "The Board believes a relative increase in the number of shares of common stock authorized for issuance in these circumstances is in the best interests of the Company and its stockholders."

Industry Context

Reverse stock splits are a common strategy for companies facing delisting from major exchanges due to low share prices. This action by PAVmed aligns with similar moves by other companies in the medical technology or biotech sector that may experience stock price volatility or challenges in meeting listing requirements. It is a compliance-driven event rather than a reflection of specific industry trends in product development or market growth.

Corporate Governance

Stakeholder Impact

• **Shareholders**: Will hold fewer shares, but each share will represent a proportionally higher value and ownership interest. Fractional shares will be rounded up. The primary benefit is the potential maintenance of Nasdaq listing, preserving liquidity and visibility for all shareholders.
• **Option/Convertible Security Holders**: Their outstanding options and convertible securities will be adjusted proportionately in terms of the number of shares and exercise/conversion prices, maintaining their economic interest in the company.

Next Steps

• Common stock will begin trading on a split-adjusted basis at the open of business on January 2, 2026.
• Stockholders holding paper certificates may send them to Continental Stock Transfer & Trust Company for new certificates reflecting the reverse split.

Key Dates

Recommendation

The reverse stock split is a necessary corporate action to maintain Nasdaq listing, addressing a compliance issue rather than reflecting a fundamental change in the company's operational performance or strategic direction. While avoiding delisting is a positive, the underlying reason (low share price) remains a concern. Investors should hold to observe if the company can sustain the higher share price and demonstrate improved business fundamentals, as the split itself does not alter the company's intrinsic value.

Keywords

PAVmed, PAVM, Reverse Stock Split, Nasdaq Compliance, Stock Split, Authorized Shares, Medical Technology, Delisting Risk, Corporate Governance, Shareholder Meeting